Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-12-14
2009-10-06
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07598262
ABSTRACT:
A method is provided for first line treatment of type 2 diabetes employing a combination of metformin and glyburide. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and/or post-prandial glucose excursion and/or hemoglobin 1Ac, and/or increase post-prandial insulin, thereby treating the diabetes.
REFERENCES:
patent: 3174901 (1965-03-01), Sterne
patent: 3979520 (1976-09-01), Rothe et al.
patent: 4060634 (1977-11-01), Rothe et al.
patent: 4916163 (1990-04-01), Ni
patent: 5258185 (1993-11-01), Bauer et al.
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5663198 (1997-09-01), Reul et al.
patent: 5922769 (1999-07-01), Barelli et al.
patent: 5965584 (1999-10-01), Ikeda et al.
patent: 6011049 (2000-01-01), Whitcomb
patent: 6153632 (2000-11-01), Rieveley
patent: 6303146 (2001-10-01), Bonhomme et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 62704 (1996-07-01), None
patent: 0749751 (1996-12-01), None
patent: 0 974 356 (2003-09-01), None
patent: 97/17975 (1997-05-01), None
patent: 98/56378 (1998-12-01), None
patent: 98/57634 (1998-12-01), None
patent: 99/03476 (1999-01-01), None
patent: 99/20275 (1999-04-01), None
patent: 99/40904 (1999-08-01), None
patent: 99/43705 (1999-09-01), None
patent: 00/15229 (2000-03-01), None
patent: 01/21159 (2001-03-01), None
Earle, et al, Acta Diabetol, 36:61-65.
Hermann et al, Diabetes Care, 17(10) Oct. 1994, 1100-1109.
Ohmura et al., Current Therapeutic Research, vol. 59, No. 12, Dec. 1998, pp. 889-895.
Drug Facts and Comparisons (1995 Edition) pp. 547.
Wang et al., Diabetic Medicine, abstract, vol. 16, Issue 6, pp. 477-481, 1999.
Haupt et al, “Oral Antidiabetic Combination Therapy with Sulfonyl Ureas and Metformin”, Med. Welt. (40, No. 5, 118-23, 1989).
Parodi et al, “Results with a Combination of Glipizide and Dimethylbiguanide in 40 Cases of Diabetes”, Gass. Med. Ital., 132/5 (226-235) 1973.
Vigneri et al, “Treatment of NIDDM Patients with Secondary Failure to Glyburide: Comparison of the Addition of Either Metformin or Bed-Time NPH Insulin to Glyburide”, Diabete & Metabolisme, 1991, 17, 232-234.
Higginbotham et al, “Double-Blind Trial of Metformin in the Therapy of Non-Ketotic Diabetes”, The Med. Journal of Australia, Aug. 11, 1979, 154-156.
Edwards et al, Combination Glipizide/Metformin Treatment Reduces Low Density Lipoprotein Binding to Arterial Proteglycane in NIDDM, Diabetes, (46, Suppl. 1, 45A, 1997).
Cefalu et al, “Combination of glipizide/Metformin Normalizes Glucose and Improves Insulin Sensitivity in Hyperinsulinemia Moderately Well Controlled”, Diabetes (45, Suppl. 2, 201A, 1996).
Crouse et al, “Effects of Combination of Glipizide/Metformin Treatment on Oxidizability of LDL in NIDDM”, Circulation (94, No. 8, Suppl., 1508, 1996).
Cefalu et al, “Insulin Sensitivity is Improved After Glipizide Monotherapy and Combination with Metformin”, Diabetologia (39, Suppl. 1, A231, 1996).
Reaven et al, “Combined Metformin-Sulfonylurea Treatment of Patients with Noninsulin-Deendent Diabetes in Fair to Poor Glycemic Control”, J. Clin. Endocrinol. Metab. (74, No. 5, 1020-26, 1992).
Hollenbeck et al, “Combination Glipizide/Metformin Treatment in Non-Insulin Dependent Diabetes (NIDDM)”, Diabetes (39, Suppl. 1, 108A, 1990).
Press Release Sep. 30, 1999: Bristol-Myers Squibb Files New Drug Application for Novel Oral Antidiabetic Drug.
Glucomide—Italian Package Insert, Repertorio Farmaceutico Italiano, 1999—with English translation.
Glibomet—Italian Package Insert, Repertorio Farmaceutico Italiano, 1999—with English translation.
Suguan M—Italian Package Insert, Repertorio Farmaceutico Italiano, 1999—with English translation.
Bi-Euglucon M—Italian Package Insert, Repertorio Farmaceutico Italiano, 1999—with English translation.
AU—A-42302, abstract, Jaenicks, May 1990.
Hermann et al, Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care, 17:1100-1109 (1994).
Aviles-Santa et al, Ann. Intern. Med., 131(3):182-188 (1999).
Daniel et al, Ann. Pharmacother., 31(4):474-480 (1997).
Scheen, Diabetes and Metabolism, 24(4):311-321 (1998).
Ratner, Today's Therapeutic Trends, 17/1:57-66, (1999).
Maislos et al, Diabetologia, 42, suppl. 1: A223, (1999).
Wolffenbuttel, Neth. J. Med., 55(5): 229-234, (1999).
Paul, Arzneim.-Forsch., 49(10):835-842, (1999), abstract.
Scheen et al, Diabetes Care, 22(9):1568-1577, (1999).
Greene, Expert Opin. Invest. Drugs, 8(10):1709-1719, (1999).
Karara et al, Pharmaceutical Research, vol. 14, No. 11, Suppl: S557, (1997).
Fonseca et al, Diabetes, 48, Suppl. 1: A100, (1999).
Suzuki et al, Diabetes, 48, Suppl. 1: A454, (1999).
Lemaire, V., “La metformine doit-ell etre associee a un sulfamide ou utilisee seule?”, Concours med., 1996, 7, p. 436-437.
Moses, R. et al., “Effect of replaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes”, Diabetes Care (1999) vol. 22(1), pp. 119-124.
R. Lupi, et al., “Effects of glibenclamide and metformin (alone or in combination) on insulin erlease from isolated human pancreatic islets”, Acta Diabetol. 34: 46-48.
Gregorio, F. et al., “Low dose metformin in the treatment of type I non-insulin-dependent diabetes mellitus: clinical and metabolic evaluations”, Acta Diabetol Lat. 1990, Apr-Jun, 27(2):139-55.
Okada, S., et al., “The effect of a very low dose of tolbutamide combined with an alpha-glucosidase inhibitor in non-insulin-dependent diabetes mellitus”, J. Int. Med. Res. 1996, Sept-Oct, 24(5): 433-7.
Purnell, J. Q. et al., “New oral therapies for type II diabetes” Am. Fam. Physician, 1997, Nov. 1., 56:(7):1835-42.
Bristol--Myers Squibb Company
Kwon Brian-Yong S
Rodney Burton
LandOfFree
Method for treating diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075641